Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Novartis : LAND CONSERVANCY GETS HELPING HANDS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/29/2016 | 01:00pm CEST

As part of the Novartis Group's 20th annual Community Partnership Day, a group of employees spent a workday at The Land Conservancy of New Jersey in Boonton.

The Land Conservancy of New Jersey is a nonprofit, member supported land trust, dedicated to preserving and protecting open spaced lands and valuable water resources.

Novartis associates raked, planted, cleared debris and brush to beautify the organization's headquarters, WildAcres, a 44-acre public park.

Worldwide, more than 27,500 Novartis associates are dedicating an estimated 220,000 hours to volunteer with charitable causes in their communities to celebrate Community Partnership Day.

These Novartis Pharmaceuticals Corporation volunteers were among more than 5,000 associates in the U.S. who provided hands-on support that benefited more than 175 nonprofit agencies.

Community Partnership Day aims to provide opportunities for associates to give their time, expertise and ideas to volunteering efforts that foster a deeper connection with the patients we support and in the communities where we live.

"Community Partnership Day has been a traditional day of volunteer service at Novartis for 20 years, bringing together associates around the world and across functions to support our nonprofit partners and the important work that they do," said Amy Fry, vice president, communications and patient relations, Novartis Pharmaceuticals Corporation. "It's a fun and rewarding day to volunteer together and support our mission of discovering new ways to extend and improve people's lives."

© (c) 2016 The Neighbor News, North Jersey Media Group, Inc. All Rights Reserved., source Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
06/23 PFIZER : Global Latanoprost Sales Market 2017 - Pfizer, Jamp Pharma, Laboratoire..
06/23 NOVARTIS : NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIF..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 HERE’S WHAT’S MOVING NOV : NVS) and Kamada Ltd (NASDAQ:KMDA)
06/23 NOVARTIS : Kisqali® (ribociclib) receives positive CHMP opinion as first-line tr..
06/23 NOVARTIS : data shows half of eligible Ph+ CML-CP patients remain in Treatment-f..
06/23 NOVARTIS : pivotal CTL019 6-month follow-up data show durable remission rates in..
06/22 NOVARTIS : combination targeted therapy Tafinlar® + Mekinist® receives FDA appro..
06/22 NOVARTIS : Medicxi launches first $300m late-stage life sciences fund Medicxi Gr..
06/22 AMGEN : AAM Biosimilars Council Praises Unanimous Supreme Court Ruling That Will..
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/23 Novartis' CAR-T candidate CTL019 shows sustained remission rates in mid-stage..
06/23 FDA OKs combination of Novartis' Tafinlar + Mekinist for BRAF V600E-positive ..
06/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 23, 2017
06/22 Artificial Intelligence Is The Real Thing For Pharma And Medtech
06/22 Drug stocks rally on GOP draft of healthcare bill
Advertisement
Financials ($)
Sales 2017 48 371 M
EBIT 2017 11 674 M
Net income 2017 7 435 M
Debt 2017 15 461 M
Yield 2017 3,28%
P/E ratio 2017 25,20
P/E ratio 2018 22,19
EV / Sales 2017 4,98x
EV / Sales 2018 4,76x
Capitalization 225 516 M
More Financials
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 81,8 $
Spread / Average Target -5,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS7.69%225 516
JOHNSON & JOHNSON17.10%366 496
ROCHE HOLDING LTD.8.81%225 056
PFIZER4.86%202 832
MERCK AND COMPANY12.15%180 576
SANOFI15.28%124 760
More Results